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1. Introduction 
Blood coagulation factor XIII is a proenzyme which 
can be activated by thrombin [I] to the transgluta- 
minase factor XIII, [2%4]. Factor XIII, catalyzes the 
formation of e(y-glutamyl)lysyl amide bonds between 
pairs of y-chains in aggregated fibrin, resulting in its 
transformation to a highly stable and insoluble cova- 
lently cross-linked clot (reviewed in [S-7]). Two other 
plasma proteins cYz-macroglobulin and fibronectin 
contain acceptor sites for factor XIII, as shown by 
incorporation of dansylcadaverine [8]. Only fibronec- 
tin, but not aa-macroglobulin, was shown to be cross- 
linked to fibrin [8]. Cross-linking of fibronectin to 
collagen [9 ,I 0] and to StaphyZoccocus aureus cells 
[ 1 l] has been demonstrated. It has also been suggested 
that rYa-antiplasmin could be covalently linked to. 
fibrin in a Ca’+dependent reaction probably catalyzed 
by factor XIII, [ 121. 
Here we report the ammo acid sequence in bovine 
fibronectin which contains the glutamine residue 
labelled with radioactive putrescine by factor XIII,. 
This glutamine is located at position 3 from the N-ter- 
minus of fibronectin. 
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2. Materials and methods 
Bovine plasma fibronectin was purified by affinity 
chromatography on gelatin agarose essentially as 
described for human plasma fibronectin [ 131. Bovine 
thrombin [ 141, human factor XIII [ 1 S] and human 
plasminogen [ 161 were purified as described. 
In the labelling experiment 1.7 g fibronectin was 
dissolved in 2.6 litres 50 mM Tris,O.l5 M NaCl, 1OmM 
CaC12 (PH 7.5) and 418 mg putrescine/2 HCl (Sigma) 
containing 250 PCi [l ,4-14C]putrescine/2 HCl(l16 
mCi/mmol, Amersham) was added. Factor XIII, 4 ml 
was activated for 1 h at 37°C with 500 units thrombin 
(1 ml factor XIII, incorporated 25 000 cpm [ 14C]- 
putrescine into casein under non-reducing conditions) 
and added to the fibronectin/putrescine solution. The 
reaction mixture was incubated at 37°C overnight and 
dialyzed for 24 h against 25 litres 0.1 M NH4HC0s 
(pH 8.3). 
Plasminogen (50 mg) was activated with 1 mg 
streptokinase (Kabi) in 100 ml 0.2 M Tris (PH 8.4) 
containing 10 mM lysine and added to the solution of 
putrescine labelled fibronectin. After incubation for 
20 h at 37°C the digestion was arrested with 20 mg 
Aprotinin (Nova). The resulting fragments were sepa- 
rated on columns of gelatin agarose (5 X 25 cm) and 
diethylaminoethyl cellulose (DE-52, Whatman) 5 X 15 
cm both equilibrated in 0.1 M NbHCOa (pH 8.3) 
and coupled in a tandem arrangement with the gelatin 
agarose as the first one. The solution was pumped 
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(120 ml/h) through the columns followed by washing 
with 1 litre 0.1 M NH4HC0s. The columns were dis- 
connected and the gelatin-agarose eluted with a linear 
gradient formed from 1 litre 0.1 M N&HCOs and 
I litre 0 .I M N&HCOs, 5 M urea (pH 8.3). The DE-52 
column was eluted with a linear gradient in NH4HC03 
(pH 8.3) (0.5 Iitre 0.1 M NH4HC0s and 0.5 litre 
0.6 M NbHCOs). Radioactivity was monitored by 
scintillation counting on 20 fl ahquots of the effluents. 
Reduction and a~ylation with iodoacetic acid of 
the &fr 29 000 fragment, digestion with trypsin and 
thermolysin, peptide separation on DEAE-Sephacel, 
high-voltage paper electrophoresis at pH 6.5 and 2.1, 
fingerprinting, autoradiography, sequencing and amino 
acid analysis were performed essentially as in [ 171. 
Putrescine was eluted from the ammo acid analyzer 
column after 134 min by extended use of the last 
buffer. Peptides were derivatised for mass spectromet- 
ric measurements according to standard procedures 
[l&l 91. Spectra were recorded on a Kratos MS50 
high-field magnet mass spectrometer operating with 
an accelerator voltage of 8 kV and an electron beam 
energy of 70 eV. 
3. Results and discussion 
Plasma fibronectin is a glycoprotein composed of 
2 disulp~de bridged chains with M, 220 000 and 
2 15 000 [ZO]. Fragmentation of fibronectin with pro- 
teolytic enzymes and chemicals has been intensively 
studied [21-271 and after digestion of [‘4C]putres- 
tine labelled fibronectin with plasmin the radioactiv- 
ity was located in a fragment with &I, 27 000 [28]. 
To determine the ammo acid sequence around the 
acceptor site in fibronectin, purified bovine fibronec- 
tin was incubated with [ 14C]putrescine and purified 
human factor XIII, under non-reducing conditions. 
The labelled ~bronectin was digested with p~asmin 
and the resulting fragments separated on columns of 
gelatin-agarose and DEAF-cellulose. Four fragments 
with M, 29 000,170 000,23 000 and 6000 had been 
isolated after digestion of unlabelled bovine fibronec- 
tin with plasmin 1291. Similar fragments were isolated 
from thelabelled fibronectin. The MI 29 000 fragment, 
which did not absorb to either of the two columns, 
contained all the radioactivity, while the MI 170 000 
eluted from the gelatin agarose and the Mr 23 000 and 
6000 fragments eluted from the DEAE-cellulose were 
free of any detectable radioactivity. The M, 29 000 
fragment was reduced, alkylated and digested with 
trypsin. The resulting peptides were separated on 
DEAE-Sephacel in a gradient of NH4HC03 followed 
by paper electrophoresis at pH 6.5 and 2.1. The 
amino acid composition of the main radioactive pep- 
tide (Tl) is shown in table 1. No sequence informa- 
tion was obtained either by direct Edman degradation 
or by dansylation of Tl . The complete amino acid 
sequence of the MI 29 000 fragment has been deter- 
mined (in prep~ation) and the amino acid composi- 
tion of Tl corresponded to the N-terminal 36 residues 
(fig.1) of this fragment. The values for proline and 
glycine are somewhat high when compared with the 
sequence due to trace peptide impurities originating 
from the gelatin column. Tl was further digested with 
thermolysin and the resulting peptides separated by 
two-dimensional paper electrophoresis at pH 6.5 and 
2.1, Peptides corresponding to residues l-4,5-1 1, 
12-l 3,28-29 and 30-36 were obtained in pure 
form as judged from amino acid compositions and 
sequencing results. Peptide material derived from resi- 
dues 14-27 did not show up after staining with fluo- 
rescamine and no further effort was made to locate 
such material because the only radioactive spot 
detected by autoradiography coincided with the posi- 
Table 1 
Amino acid composition of the peptide labelled with putles- 
tine by factor XIII, and isolated after digestion with trypsin 
a 
Cmc 0.4 1 
Asx 3.1 3 
Thr 1 .o 1 
Ser 2.7 3 
GlX 9.2 10 
Pro 4.3 3 
GUY 3.0 2 
Ala 1.2 1 
Val 2.0 2 
Met 0.0 0 
Ile 1.7 2 
Leu 1.1 1 
Tyr 2.0 2 
Phe 0.0 0 
LYS 2.1 2 
His 1 .o 1 
TIP n.d. 1 
Ax 1.0 1 
Putrescine 
a From the sequence 
09 
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1 J 5 10 15 20 
<Glu-Ala-G1 n-Gln-Ile-Val-Gln-Pro-Gln-Ser-Pro-Leu-Thr-Val-Ser-Gln-Cys-Lys-Pro-Gly- 
25 30 35 
-Ser-Tyr-Asp-Asn-Gly-Lys-His-Tyr-Gln-Ile-Asn-Gln-Gln-Trp-Glu-Arg- 
Fig.1. The N-terminal 36 residues of bovine plasma fibronectin. The (&) indicates the glutamine residue to where putrescine is 
linked by factor XIII,. 
tion of peptide l-4. The amino acid composition of 
this peptide was Glx 3 S, Ala 1 .O, putrescine 0.9. After 
deuteroacetylation and permethylation of this peptide 
the electron impact mass spectrum shown in fig.2 was 
obtained. This spectrum allows the assignment of the 
sequence as: 
<Glu-Ala-Glx- 
I 
Putrescine 
from the signals at m/e 98,211,469 and 497 as indi- 
cated in fig.2. For comparison the same peptide was 
PCA-Alo ~--, 
isolated from unlabelled fibronectin and after deutero- 
acetylation and permethylation the electron-impact 
mass spectrum obtained is shown in fig.3. In agree- 
ment with the expected sequence: 
<Glu-Ala-Gln- 
the signals at m/e 98,2 11,3 53 and 381 were found. 
Immonium ion fragments (HaC-p=CH-R) are 
observed at m/e 259 (R = (CH&CO-N(CH,)- 
(CH&-N(CHa)-CO-C*Ha) and m/e 143 (R = 
(CH,),CO-N(CH,),) in fig.2 and 3, respectively. 
Neither of the two peptides yielded a molecular ion. 
Lb0 
Fig.2. The electron-impact mass spectrum obtained at 260°C of the deuteroacetylated permethylated peptide (residues l-4) con- 
taining the putrescine label. 
100 200 m/e 300 400 
Fig.3. The electron-impact mass spectrum obtained at 260°C of the unlabelled deuteroacetylated permethylated peptide (residues 
l-4). 
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This is probably due to a rapid cyclisation and cleav- 
age of the C-terminal Gln4 resulting in pyroglutamic 
acid fragments. 
Two other radioactive peptides were detected in 
the effluent from the DEAF-Sephacel column and 
after further purification by high-voltage paper elec- 
trophoresis at pH 6.5 and 2.1 shown to correspond to 
positions 1-l 2 and l-26, respectively, in fig.1. No 
N-terminus was found by dansylation or Edman degra- 
dation. After digestion with thermolysin followed by 
two-dimensional fingerprinting at pH 6.5 and 2 .l both 
peptides gave rise to the same radioactive peptide cor- 
responding to positions l-4 in fig.1. 
In fig.4 the acceptor sites for factor XIII, in human 
fibrinogen [30,3 I] bovine &casein [32] and bovine 
fibronectin have been aligned. No sequence homology 
is obvious. As in fibronectin it is the first of 2 consec- 
utive glutamine residues in the y-chain of fibrinogen 
which is labelled [30]. 
Our results show that putrescine is linked to the 
Gln residue located at position 3 iri bovine fibronec- 
tin, and no indication for incorporation of putrescine 
into the Gln residue at position 4, other of the Gln 
residues at positions 7,9,16,29,32 and 33 or any 
other positions in fibronectin has been found. The 
labelling was performed under non-reducing condi- 
tions in order to keep the fibronectin as native as pos- 
sible. Whether a reducing agent in the reaction mixture 
will result in the labelling of other positions in fibro- 
nectin was not investigated. 
The abnormal scar formation in patients deficient 
in factor XIII 133,343, the effect of factor XIII on 
the growth of ~broblasts in celf culture [34] and the 
in vitro cross-linking of fibronectin to fibrin and col- 
lagen by factor XIII, [8-101 indicate that e(y-glu- 
tamyl)lysyl amide bonds are of physiological impor- 
tance not only between y-chains of fibrin but more 
generally in the matrix of connective tissue. The iden- 
tification of a potential cross-linking site in plasma 
fibronectin should facilitate the isolation and charac- 
terization of cross-links formed in vivo to fibronectin. 
The first 6 residues in human fibronectin have been 
determined [26] as: 
The requirement for fibronectin in the opsoniza- 
tion of foreign particulate matter [36] by the retic- 
uloendothelial system and the suggested involvement 
of transglutaminases in receptor-mediated endocyto- 
sis [37] raise the question whether the Gln-residue in 
position 3 in fibronectin have a specific function in 
connection with the transport of fibronectin-coated 
particles through membranes. 
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397 
fibrinogen y-chain human -Thr-Ile-Gly-Glu-Gly-Gln-Gln-His-His-Leu-Gly- 
328 
fibrinogen a-chain human -Gly-Ser-Thr-Gly-Asn-Gln-Asn-Pro-Gly-Ser-Pro- 
366 
fibrinogen a-chain human -Ser-Gly-Ser-Thr-Gly-Gln-Trp-His-Ser-Glu-Ser- 
167 
B-casein bovine -Val-Leu-Ser-Leu-Ser-Gln-Ser-Lys-Val-Leu-Pro- 
3 
plasma fibronectin bovine <Glu-Ala-Gln-rJln-Ile-Val-Gln-Pro- 
Fig.4. Alignment of the factor XIII, acceptor sites in fibrinogen [ 30,311 p-casein [ 32,351 and plasma fibronectin. The numbers 
indicate the positions of the sites in the respective chains. 
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